|
private label Acne Care gets high marks from consumers Johnson & Johnson’s Neutrogena leads the way in this $671 million category, but private label and select brands posted |
||||||
|
Brand |
Dollar Sales |
Dollar Share of SubCategory |
Unit Sales |
|||
|
Current |
% Change vs YA |
Current |
Change vs YA |
Current |
% Change vs YA |
|
|
Acne Treatments |
$671,601,560 |
14.6% |
100.00 |
0.00 |
88,578,846 |
2.7% |
|
Neutrogena |
$148,303,237 |
-11.4% |
22.08 |
-6.48 |
20,444,842 |
-13.1% |
|
Private Label |
$146,936,538 |
106.3% |
21.88 |
9.72 |
21,276,392 |
37.9% |
|
Differin |
$71,550,843 |
23.6% |
10.65 |
0.77 |
4,271,810 |
24.1% |
|
Panoxyl |
$46,240,270 |
98.9% |
6.89 |
2.92 |
4,639,247 |
107.7% |
|
Clean & Clear |
$40,856,162 |
-18.2% |
6.08 |
-2.44 |
6,708,157 |
-19.2% |
|
Cerave |
$25,548,702 |
96.0% |
3.80 |
1.58 |
1,933,319 |
86.0% |
|
Clearasil |
$25,281,790 |
-25.1% |
3.76 |
-2.00 |
3,600,481 |
-22.7% |
|
Aveeno |
$19,351,107 |
-9.0% |
2.88 |
-0.75 |
2,175,221 |
-12.6% |
|
St. Ives |
$19,039,036 |
-20.8% |
2.83 |
-1.27 |
4,181,105 |
-21.2% |
|
La Roche Posay |
$16,614,786 |
53.1% |
2.47 |
0.62 |
759,236 |
55.3% |
|
Oxy |
$13,875,838 |
-6.3% |
2.07 |
-0.46 |
2,448,122 |
-9.1% |
|
Noxzema |
$10,436,738 |
-9.2% |
1.55 |
-0.41 |
2,435,387 |
-8.1% |
|
Stridex |
$8,183,077 |
-9.4% |
1.22 |
-0.32 |
2,000,774 |
-10.8% |
|
Biore |
$8,110,144 |
-33.4% |
1.21 |
-0.87 |
1,173,353 |
-34.2% |
|
Burt’s Bees |
$8,080,174 |
-24.8% |
1.20 |
-0.63 |
942,907 |
-24.2% |
|
Alba |
$7,812,799 |
18.8% |
1.16 |
0.04 |
1,058,750 |
16.0% |
|
Acnefree |
$6,508,608 |
-11.2% |
0.97 |
-0.28 |
831,290 |
-2.4% |
|
Hanhoo |
$5,776,501 |
53.7% |
0.86 |
0.22 |
1,939,241 |
33.1% |
|
Yes To |
$4,118,713 |
-51.0% |
0.61 |
-0.82 |
551,404 |
-51.1% |
|
Asepxia |
$3,929,254 |
-13.4% |
0.59 |
-0.19 |
899,825 |
-12.8% |
|
Source: IRI Market Advantage—TSV |
||||||